Page last updated: 2024-12-06
oxisuran
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
oxisuran: proposed antineoplastic & immunosuppressive agent; minor descriptor (75-86); on-line & INDEX MEDICUS search PYRIDINES (75-86) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 33770 |
| CHEMBL ID | 2106596 |
| SCHEMBL ID | 4657 |
| MeSH ID | M0263359 |
Synonyms (43)
| Synonym |
|---|
| 2-methylsulfinyl-1-(2-pyridyl)ethanone |
| 2-(methylsulfinyl)-1-(2-pyridinyl)ethanone |
| pyridine, {2-[(methylsulfinyl)acetyl]-} |
| {2-[(methylsulfinyl)acetyl]pyridine} |
| oxisuran |
| 2-[(methylsulfinyl)acetyl]pyridine |
| (methylsulfinyl)methyl 2-pyridyl ketone |
| ketone, (methylsulfinyl)methyl 2-pyridyl |
| pyridine, 2-[(methylsulfinyl)acetyl]- |
| ethanone, 2-(methylsulfinyl)-1-(2-pyridinyl)- |
| 27302-90-5 |
| w 6495 |
| ismisupren |
| nsc-356716 |
| nsc356716 |
| ccris 489 |
| oxisuranum [inn-latin] |
| 2-((methylsulfinyl)acetyl)pyridine |
| oxisurano [inn-spanish] |
| oxisuran [usan:inn] |
| pyridine, 2-((methylsulfinyl)acetyl)- |
| brn 1526159 |
| nsc 356716 |
| oxisuran (usan/inn) |
| D05305 |
| 2-methylsulfinyl-1-pyridin-2-ylethanone |
| AKOS006271449 |
| w-6495 , |
| CHEMBL2106596 |
| 5-21-12-00151 (beilstein handbook reference) |
| njm3553dh2 , |
| oxisuranum |
| oxisurano |
| unii-njm3553dh2 |
| (+/-)-ethanone, 2-(methylsulfinyl)-1-(2-pyridinyl)- |
| oxisuran [usan] |
| oxisuran [inn] |
| SCHEMBL4657 |
| SR-01000945003-1 |
| sr-01000945003 |
| Q27284895 |
| DTXSID60865359 |
| 2-(methanesulfinyl)-1-(pyridin-2-yl)ethan-1-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||